retatrutide peptide trials clinical status trial Retatrutide, an experimental weight-loss drug, has not been approved by the retatrutide Retatrutide: Complete Triple Agonist Research

Sattele, his weight loss program, and all of his staff

It works the same way mechanistically, activating the GLP-1 receptor to reduce appetite, slow gastric emptying and improve insulin sensitivity, but the small molecule structure means it can be taken orally with fewer absorption constraints. In trials, orforglipron lowered blood sugar and produced meaningful weight loss in people with obesity and in those with type 2 diabetes, says LaValle

GLP-1 receptors are expressed both centrally (in the brain) and peripherally (in immune cells, the gut, and metabolic tissues)

For women considering pregnancy, understanding GLP-1 use during breastfeeding and tirzepatide during breastfeeding is essential

By target indication, the type 2 diabetes segment held a major market share of approximately 55% in 2025